Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000806773 | SCV000946790 | likely benign | Maple syrup urine disease | 2024-11-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002534833 | SCV003609431 | uncertain significance | Inborn genetic diseases | 2021-10-20 | criteria provided, single submitter | clinical testing | The c.1252G>A (p.A418T) alteration is located in exon 9 (coding exon 9) of the BCKDHA gene. This alteration results from a G to A substitution at nucleotide position 1252, causing the alanine (A) at amino acid position 418 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000806773 | SCV003829808 | uncertain significance | Maple syrup urine disease | 2019-01-31 | criteria provided, single submitter | clinical testing | |
Gene |
RCV005004437 | SCV005628481 | uncertain significance | not provided | 2024-07-17 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Natera, |
RCV001830757 | SCV002088180 | likely benign | Maple syrup urine disease type 1A | 2021-07-27 | no assertion criteria provided | clinical testing |